Dual Inhibition of IRE1α and YAP Signaling as a Potential Therapy for Epithelial Ovarian Carcinoma.

IF 0.8 4区 医学 Q4 IMMUNOLOGY
Fei Liu, Chunhua Tu, Buzhen Tan, Linsheng He, Yuan Wen
{"title":"Dual Inhibition of IRE1α and YAP Signaling as a Potential Therapy for Epithelial Ovarian Carcinoma.","authors":"Fei Liu, Chunhua Tu, Buzhen Tan, Linsheng He, Yuan Wen","doi":"10.1615/CritRevImmunol.2025057246","DOIUrl":null,"url":null,"abstract":"<p><p>Epithelial ovarian carcinoma (EOC) is a highly lethal gynecological malignancy with limited treatment options. This study aimed to explore the regulatory roles of IRE1α and YAP1 in EOC progression and identify potential therapeutic targets. Blood and tissue samples were collected from 26 EOC patients and 10 patients with ovarian cysts. The expression of inflammatory factors in the blood was measured using ELISA. The proliferation, migration, invasion, and cell cycle of human ovarian cancer cell lines SK-OV-3, SW626, and Anglene were evaluated using MTT assays, scratch tests, Transwell assays, and flow cytometry. The effects of IRE1α inhibition on EOC cell proliferation, migration, and apoptosis were investigated using pharmacological inhibitors and shRNA knockdown. IRE1α was highly expressed in EOC patients and was negatively correlated with patient survival rates. Additionally, IRE1α scores in EOC patients were positively correlated with serum levels of TNF-α and VEGF-a. Compared to normal controls, significantly higher expressions of IRE1α and XBP1 were observed in ovarian cancer tissues and cells. Knockdown of IRE1α in ovarian cancer cells led to a significant reduction in the expression of IRE1α and XBP1s, as well as inhibited cell proliferation and survival. The IRE1α inhibitors STF-083100 and 4μ8C suppressed the proliferation, invasion, and migration of SK-OV-3 cells and reduced the expression levels of related factors. 4μ8C inhibited the degradation of YAP within SK-OV-3 cells while downregulating the expression of Cyclin D1 protein. Compared to the group treated with 4μ8C alone, the combined intervention of 4μ8C and a YAP inhibitor showed a more pronounced inhibitory effect on the proliferation of SK-OV-3 cells.This study first reveals that the IRE1α/YAP signal drives the malignant progression of EOC through the regulation of cell proliferation, migration, and invasion. The dual-targeted synergistic inhibition of IRE1α/YAP1 offers an innovative therapeutic paradigm for the treatment of EOC.</p>","PeriodicalId":55205,"journal":{"name":"Critical Reviews in Immunology","volume":"45 3","pages":"19-32"},"PeriodicalIF":0.8000,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Critical Reviews in Immunology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1615/CritRevImmunol.2025057246","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"IMMUNOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Epithelial ovarian carcinoma (EOC) is a highly lethal gynecological malignancy with limited treatment options. This study aimed to explore the regulatory roles of IRE1α and YAP1 in EOC progression and identify potential therapeutic targets. Blood and tissue samples were collected from 26 EOC patients and 10 patients with ovarian cysts. The expression of inflammatory factors in the blood was measured using ELISA. The proliferation, migration, invasion, and cell cycle of human ovarian cancer cell lines SK-OV-3, SW626, and Anglene were evaluated using MTT assays, scratch tests, Transwell assays, and flow cytometry. The effects of IRE1α inhibition on EOC cell proliferation, migration, and apoptosis were investigated using pharmacological inhibitors and shRNA knockdown. IRE1α was highly expressed in EOC patients and was negatively correlated with patient survival rates. Additionally, IRE1α scores in EOC patients were positively correlated with serum levels of TNF-α and VEGF-a. Compared to normal controls, significantly higher expressions of IRE1α and XBP1 were observed in ovarian cancer tissues and cells. Knockdown of IRE1α in ovarian cancer cells led to a significant reduction in the expression of IRE1α and XBP1s, as well as inhibited cell proliferation and survival. The IRE1α inhibitors STF-083100 and 4μ8C suppressed the proliferation, invasion, and migration of SK-OV-3 cells and reduced the expression levels of related factors. 4μ8C inhibited the degradation of YAP within SK-OV-3 cells while downregulating the expression of Cyclin D1 protein. Compared to the group treated with 4μ8C alone, the combined intervention of 4μ8C and a YAP inhibitor showed a more pronounced inhibitory effect on the proliferation of SK-OV-3 cells.This study first reveals that the IRE1α/YAP signal drives the malignant progression of EOC through the regulation of cell proliferation, migration, and invasion. The dual-targeted synergistic inhibition of IRE1α/YAP1 offers an innovative therapeutic paradigm for the treatment of EOC.

IRE1α和YAP信号双重抑制作为上皮性卵巢癌的潜在治疗方法。
上皮性卵巢癌(EOC)是一种高度致命的妇科恶性肿瘤,治疗方案有限。本研究旨在探讨IRE1α和YAP1在EOC进展中的调节作用,并确定潜在的治疗靶点。本文采集了26例卵巢囊肿患者和10例卵巢囊肿患者的血液和组织样本。采用ELISA法检测血中炎症因子的表达。采用MTT试验、划痕试验、Transwell试验和流式细胞术评价人卵巢癌细胞株SK-OV-3、SW626和Anglene的增殖、迁移、侵袭和细胞周期。通过药理抑制剂和shRNA敲低研究IRE1α抑制对EOC细胞增殖、迁移和凋亡的影响。IRE1α在EOC患者中高表达,且与患者生存率呈负相关。此外,EOC患者的IRE1α评分与血清TNF-α和VEGF-a水平呈正相关。与正常对照组相比,IRE1α和XBP1在卵巢癌组织和细胞中的表达明显升高。在卵巢癌细胞中,敲低IRE1α可显著降低IRE1α和XBP1s的表达,抑制细胞增殖和存活。IRE1α抑制剂STF-083100和4μ8C抑制SK-OV-3细胞的增殖、侵袭和迁移,降低相关因子的表达水平。4μ8C抑制SK-OV-3细胞内YAP的降解,下调Cyclin D1蛋白的表达。与4μ8C单独干预组相比,4μ8C联合YAP抑制剂对SK-OV-3细胞的增殖抑制作用更为明显。本研究首次揭示了IRE1α/YAP信号通过调控细胞增殖、迁移和侵袭来驱动EOC的恶性进展。IRE1α/YAP1的双靶点协同抑制为EOC的治疗提供了一种创新的治疗模式。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
2.60
自引率
0.00%
发文量
14
审稿时长
>12 weeks
期刊介绍: Immunology covers a broad spectrum of investigations at the genes, molecular, cellular, organ and system levels to reveal defense mechanisms against pathogens as well as protection against tumors and autoimmune diseases. The great advances in immunology in recent years make this field one of the most dynamic and rapidly growing in medical sciences. Critical ReviewsTM in Immunology (CRI) seeks to present a balanced overview of contemporary adaptive and innate immune responses related to autoimmunity, tumor, microbe, transplantation, neuroimmunology, immune regulation and immunotherapy from basic to translational aspects in health and disease. The articles that appear in CRI are mostly obtained by invitations to active investigators. But the journal will also consider proposals from the scientific community. Interested investigators should send their inquiries to the editor before submitting a manuscript.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信